UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063637
Receipt number R000072744
Scientific Title Outcomes of T2DM Outpatients: Medical AI Optimization (O-TOMO): A Randomized Controlled Trial
Date of disclosure of the study information 2026/11/16
Last modified on 2026/11/16 09:18:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the Effectiveness of AI-Based Health Support for Patients with Type 2 Diabetes

Acronym

Evaluation of the Effectiveness of AI-Based Health Support for Patients with Type 2 Diabetes

Scientific Title

Outcomes of T2DM Outpatients: Medical AI Optimization (O-TOMO): A Randomized Controlled Trial

Scientific Title:Acronym

Outcomes of T2DM Outpatients: Medical AI Optimization (O-TOMO): A Randomized Controlled Trial

Region

Japan


Condition

Condition

Type 2 diabetes mellitus (T2DM)

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the impact of an artificial intelligence (AI)-driven health support tool (O-TOMO) on self-care indicators in patients with type 2 diabetes.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The change in the Summary of Diabetes Self-Care Activities (J-SDSCA) score from baseline to the third outpatient visit in the intervention group compared with the control group.

Key secondary outcomes

Secondary Endpoint 1:
Change in the mean total score obtained from the PAM-13 (Patient Activation Measure) or alternative scales evaluating self-efficacy and empowerment (e.g., PEPPI-10, J-SEMCD-6, CHAI) before and after the first visit, as well as from the first visit to the third outpatient visit.
Secondary Endpoint 2:
Mean or aggregate score of the safety and accuracy of AI-generated summaries based on clinical experts' evaluation.
Secondary Endpoint 3:
Responses (feedback) obtained from semi-structured interviews exploring healthcare providers' and patients' experiences with O-TOMO.
Secondary Endpoint 4:
Evaluation of treatment plan adherence rate based on a patient questionnaire (compliance survey regarding treatment plans, clinic visits, etc., e.g., presence or absence of appointment reschedules/cancellations).
Exploratory Endpoint 1:
Change in HbA1c from baseline to the third outpatient visit, compared with the control group.
Exploratory Endpoint 2:
Change in total scores or other metrics obtained from caregiver questionnaire responses using either the BIC-11 (Burden Index of Caregiver) or the CRA-J-10 (Caregiver Reaction Assessment Japanese version 10 items).


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Use of the Smartphone Application (O-TOMO) Over Three Outpatient Visits (3-4 Month Period)

Interventions/Control_2

Usual Outpatient Care (Control Group)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients:
1. Age: Adults (18 years of age or older)
2. Scheduled Visit: Must have a scheduled appointment with a primary care/attending physician at our hospital in one of the outpatient clinics participating in this study.
3. Treatment & Follow-up Expectation: Must have scheduled appointments for the continuous management of type 2 diabetes and be expected to complete 3 outpatient visits within the 3-to-4-month study period.
4. Language Ability: Must be able to read and write Japanese.
5. Internet Access: Must have access to Wi-Fi or the Internet.

Caregivers:
1. Age: Adults (18 years of age or older)
2. Role: Family members or equivalent individuals providing care for the patient (study participant).

Key exclusion criteria

Patients:
1. Emergency Medical Condition: Conditions requiring emergency medical care.
2. Pregnancy: Currently pregnant (based on self-report or medical records).
3. Other Disqualifying Conditions: Any other medical condition or reason that, in the judgment of the Principal Investigator or Sub-Investigator, may interfere with study participation, study procedures, or data collection.
4. Prior Participation: Individuals who have previously participated in this study.
5. Lack of Caregiver Consent: Patients requiring assistance or accompaniment from family members or caregivers for daily self-care or clinic visits, for whom consent to participate in this study cannot be obtained from the respective family member or caregiver.

Caregivers:
1. Difficulty Providing Support: Individuals with difficulty reading or writing Japanese, or any condition making it difficult to support the patient's use of the O-TOMO tool.
2: Prior Participation: Individuals who have previously participated in this study.

Target sample size

124


Research contact person

Name of lead principal investigator

1st name Yuichiro
Middle name
Last name Yano

Organization

Juntendo University

Division name

Department of General Medicine

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

+81-3-3813-3111

Email

y.yano@juntendo.ac.jp


Public contact

Name of contact person

1st name Yuichiro
Middle name
Last name Yano

Organization

Juntendo University

Division name

Department of General Medicine

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

+81-3-3813-3111

Homepage URL


Email

y.yano@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Google LLC

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee, Faculty of Medicine, Juntendo University

Address

3-1-3 Hongo, Bunkyo-ku, Tokyo

Tel

03-3814-5672

Email

hongo-rinri@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 11 Month 06 Day

Date of IRB

2027 Year 11 Month 06 Day

Anticipated trial start date

2026 Year 12 Month 04 Day

Last follow-up date

2027 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 16 Day

Last modified on

2026 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072744